PURPOSE: To assess the contribution of concurrent low-dose, noncontrast CT in the assessment of the malignant potential of incidental focal 2-deoxy-2-[F-18]fluoro-D-glucose (FDG)-avid colonic lesions on positron emission tomography/computed tomography (PET/CT). PROCEDURES: Routine FDG-PET/CT scans were reviewed for identification of focal FDG-avid colon lesions, and the CT component was independently reviewed for an anatomical lesion and malignant potential based on CT criteria. Clinical, endoscopic, and histopathology follow-up was obtained. RESULTS: A total of 85/2,916 (3%) oncology FDG-PET/CT scans had incidental focal colon lesions. Clinical and/or endoscopic follow-up was available in 83/85 (98%) patients. Focal, corresponding CT lesions were found in 44/83 (53%) patients, but features of malignancy were not assessable. Of the 44 patients with a final diagnosis, 32/44 (73%) were FDG-PET/CT true positives; 5/44 (11%) were false positives; and 7/44 (16%) had inconclusive FDG-PET/CT findings. CONCLUSIONS: Concurrent low-dose, noncontrast CT improves localization, but does not provide independent information on the malignant potential of incidental focal colonic activity on FDG-PET/CT.
PURPOSE: To assess the contribution of concurrent low-dose, noncontrast CT in the assessment of the malignant potential of incidental focal 2-deoxy-2-[F-18]fluoro-D-glucose (FDG)-avid colonic lesions on positron emission tomography/computed tomography (PET/CT). PROCEDURES: Routine FDG-PET/CT scans were reviewed for identification of focal FDG-avid colon lesions, and the CT component was independently reviewed for an anatomical lesion and malignant potential based on CT criteria. Clinical, endoscopic, and histopathology follow-up was obtained. RESULTS: A total of 85/2,916 (3%) oncology FDG-PET/CT scans had incidental focal colon lesions. Clinical and/or endoscopic follow-up was available in 83/85 (98%) patients. Focal, corresponding CT lesions were found in 44/83 (53%) patients, but features of malignancy were not assessable. Of the 44 patients with a final diagnosis, 32/44 (73%) were FDG-PET/CT true positives; 5/44 (11%) were false positives; and 7/44 (16%) had inconclusive FDG-PET/CT findings. CONCLUSIONS: Concurrent low-dose, noncontrast CT improves localization, but does not provide independent information on the malignant potential of incidental focal colonic activity on FDG-PET/CT.
Authors: Perry J Pickhardt; J Richard Choi; Inku Hwang; James A Butler; Michael L Puckett; Hans A Hildebrandt; Roy K Wong; Pamela A Nugent; Pauline A Mysliwiec; William R Schindler Journal: N Engl J Med Date: 2003-12-01 Impact factor: 91.245
Authors: Peter B Cotton; Valerie L Durkalski; Benoit C Pineau; Yuko Y Palesch; Patrick D Mauldin; Brenda Hoffman; David J Vining; William C Small; John Affronti; Douglas Rex; Kenyon K Kopecky; Susan Ackerman; J Steven Burdick; Cecelia Brewington; Mary A Turner; Alvin Zfass; Andrew R Wright; Revathy B Iyer; Patrick Lynch; Michael V Sivak; Harold Butler Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: Neeta Pandit-Taskar; Heiko Schöder; Mithat Gonen; Steven M Larson; Henry W D Yeung Journal: AJR Am J Roentgenol Date: 2004-10 Impact factor: 3.959
Authors: Jose M Pereira; Claude B Sirlin; Pedro S Pinto; R Brooke Jeffrey; Damien L Stella; Giovanna Casola Journal: Radiographics Date: 2004 May-Jun Impact factor: 5.333
Authors: Lin Xiong; Kedar N Chintapalli; Gerald D Dodd; Shailendra Chopra; Joe A Pastrano; Cheryl Hill; John R Leyendecker; Robert M Abbott; David Grayson; John Feig Journal: AJR Am J Roentgenol Date: 2004-04 Impact factor: 3.959
Authors: Richdeep S Gill; Troy Perry; Jonathan T Abele; Eric L R Bédard; Daniel Schiller Journal: World J Surg Oncol Date: 2012-01-27 Impact factor: 2.754